Carter Milner, MD
Hematology & Oncology · Jackson, MSNPI 1538322011
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $210,670 of the $247,807 with a category attached, or 85.0%. 60 manufacturers reported payments, led by AstraZeneca at 26.0% of the total. Reporting peaked in 2022 at $79,680 and has fallen 67.8% since, to $25,692 in 2025. Among hematology & oncology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 619 payments — averaging $400.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$64K
- E.r. Squibb & Sons, L.L.C.$52K
- Beigene USA, Inc.$47K
- Blueprint Medicines Corporation$36K
- Bristol Myers Squibb$25K
- Beone Medicines USA, Inc.$11K
- plus $13K from 54 others
Across 8 payments — averaging $1810.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$10K
- Amgen$3K
- Sanofi$1K
- Novartis$540
What the payments were for
- Consulting fees$17,8457%
- Speaking & faculty fees$210,67085%
- Travel & lodging$7,9453%
- Food & beverage$10,9974%
- Education$3510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$247,807 in reported general payments places this provider in the 95th percentile of 57 hematology & oncology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 82 | $1,156,057 |
| RevlimidLenalidomide | 57 | $939,674 |
| PromactaEltrombopag Olamine | 36 | $750,859 |
| SolirisEculizumab | 25 | $682,752 |
| BrukinsaZanubrutinib | 20 | $280,218 |
| CalquenceAcalabrutinib Maleate | 19 | $258,240 |
| ImbruvicaIbrutinib | 14 | $219,894 |
| VenclextaVenetoclax | 33 | $146,984 |
| SprycelDasatinib | 13 | $121,489 |
| Imatinib Mesylate | 24 | $53,058 |
| XareltoRivaroxaban | 35 | $36,191 |
| EliquisApixaban | 52 | $33,259 |
| OxycontinOxycodone Hcl | 12 | $11,111 |
| Metaxalone | 12 | $2,937 |
| Fluconazole | 54 | $2,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris, Calquence | $64,422 | $940,99244 claims |
| Bristol Myers SquibbRevlimid | $24,744 | $939,67457 claims |
| NovartisPromacta | $732 | $750,85936 claims |
| Beigene USA, Inc.Brukinsa | $46,743 | $280,21820 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $46 | $219,89414 claims |
| AbbVieVenclexta | $256 | $146,98433 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $52,058 | $121,48913 claims |
| Johnson & JohnsonXarelto | $4,176 | $36,19135 claims |
| PfizerEliquis | $314 | $33,25952 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $26 | $2,223149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 hematology & oncology providers in Mississippi.
Other hematology & oncology in Jackson
- Guangzhi QuJackson$59K
- John HeneganJackson$35K
- Barbara CraftJackson$11K
- Grace ShumakerJackson$7K
- Justin BakerJackson$3K
- Katherine ThielJackson$2K
- Bobby WilkersonJackson$2K
- Solly ChedidPascagoula$1.7M
- Jennifer EubanksMeridian$44K
- Daniel PattersonPascagoula$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.